Jean-Marc Huet has been named senior vice president and chief financial officer, Bristol-Myers Squibb, effective March 31, 2008. Mr. Huet will be responsible for directing and managing the company’s fiscal operations, as well as the global financial operations of the organization and its subsidiaries. Andrew Bonfield, executive vice president and chief financial officer, will remain until Mr. Huet’s arrival. He will leave the company after a period of transition to seek new career opportunities.
   
Jim Cornelius, chairman and chief executive officer, praised Mr. Bonfield: “He instituted new processes and procedures to modernize the company’s financial reporting and streamlined the global finance organization to deliver superior financial support. We are pleased he has agreed to stay with the company for a period of time to support the transition to Jean-Marc, whom Andrew helped identify as a potential successor in 2007 when he began to discuss with me new challenges to further develop his career.”
   
Prior to joining the company, Mr. Huet served as chief financial officer at Royal Numico N.V. in Amsterdam. He is credited with initiating and developing Numico’s acquisition strategy within the consolidating baby food sector and its resulting acquisition by Groupe Danone. Prior to joining Royal Numico, N.V., he was an executive director, Investment Banking Services, at Goldman Sachs International in London. He also spent several years at Clement Trading in Milan, Italy, as a commercial manager.
   
In its 4Q07 statement, BMS disclosed a $275 million loss to write down structure debt investments, which included exposure to sub prime mortgages. A BMS spokesman contended that Mr. Bonfield’s departure was unrelated to this disclosure.
   
Also, Lamberto Andreotti, currently executive vice president and chief operating officer, Worldwide Pharmaceuticals, will assume responsibility for Mead Johnson and ConvaTec, and has been named executive vice president and chief operating officer of Bristol-Myers Squibb.
   
“Lamberto and Elliott Sigal, M.D., Ph.D., executive vice president and chief scientific officer, continue to help shape and drive the transformation of Bristol-Myers Squibb to a next-generation BioPharma leader,” said Mr. Cornelius. “As we continue to evolve, Lamberto and Elliott, together with the members of our Management Council, will play vital roles in shaping the Bristol-Myers of the future.
   
“We are also announcing several important internal promotions and changes of responsibility of senior management to allow us to focus on key elements of our next generation BioPharma strategy,” Mr. Cornelius added.
   
John Celentano, formerly president of the Health Care Group, has been appointed senior vice president, strategy and productivity transformation, a new position at the company. He will be responsible for strategy, corporate and business development, and information management and global shared services and will continue to lead the company’s Productivity Transformation Initiative.
   
Brian Daniels, M.D., senior vice president, global development, will join the Management Council, the company’s most senior leadership group. Together with Dr. Sigal, Dr. Daniels will drive the company’s “focus on science and medicine as a central strategy of the next-generation BioPharma vision,” according to a press statement.
   
Anthony McBride, Ph.D., has been promoted to senior vice president of human resources. Dr. McBride, who will also join the Management Council, succeeds Stephen Bear, who will retire later this month.
   
Robert Zito, senior vice president and chief communications officer, will assume oversight of the BMS Foundation, adding John Damonti, president of the Foundation, to his leadership team.